New drug cocktail shows promise for Hard-to-Treat myeloma
NCT ID NCT07150091
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 32 times
Summary
This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of four drugs: belantamab mafodotin, nirogacestat, lenalidomide, and dexamethasone. The goal is to find a safe dose and see how well the combination works at shrinking the cancer. About 20 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Salvador, Estado de Bahia, 41253-190, Brazil
-
GSK Investigational Site
São Paulo, 04537-080, Brazil
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Hamburg, 22083, Germany
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Mexico City, 01330, Mexico
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
Conditions
Explore the condition pages connected to this study.